Drawing for ULTRAGENYX

USPTO serial 97980518

ULTRAGENYX

Reviewed by CopyMark Law Group

Reg. 7907676Status 700Registered
Filing date
Status date
Registration date
Aug 19, 2025
Examiner
HELLMAN, ELI J
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with ULTRAGENYX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Brian Focarino

Brian Focarino Cooley LLP1299 Pennsylvania Avenue, NW, Suite 700ATTN: IP Docketing DepartmentWashington, DC 20004-2400

Goods and services

ClassDescriptionStatusFirst use
001Chemical, biological, and biochemical preparations for use in gene delivery technology, namely, nucleic acids, including, coding and non-coding deoxyribonucleic acids, plasmids, vectors, promotors, enhancers and other regulatory sequences, for use in vitro laboratory use; chemical, biological, and biochemical preparations for use in the manufacture of pharmaceutical preparationsACTIVE—
005Pharmaceutical preparations for the treatment of liver, hepatological, cardiovascular, central nervous system, inflammatory, autoimmune, musculoskeletal, ophthalmologic, respiratory, osteopathic, oncologic, endocrine, orthopedic, metabolic, lipid-related, genetic, neuromuscular, autosomal, lysosomal storage, enzyme, hematologic and long-chain fatty acid oxidation disorders (LC-FAOD) diseases and disorders; chemical, biological, and biochemical preparations for use in gene delivery technology for medical use, namely, nucleic acids, including coding and non-coding deoxyribonucleic acids, plasmids, vectors, promotors, enhancers and other regulatory sequences, for use in in vivo therapeutic use in gene therapyACTIVE—
016Printed publications, namely, books, brochures, informational pamphlets, informational cards, and advertisements being signs and boards of paper in the field of rare diseases and disordersACTIVE—
036Financial and insurance consultation services, namely, patient advisory, support and consultancy services regarding patient finances, insurance and access to medical treatment; providing financial and insurance information, namely, providing information and guidance in connection with health insurance benefit plans and other patient financial assistance resources; financial and insurance consultation services, namely, insurance and medical and pharmaceutical access consultation services, namely, assisting patients and their caregivers to identify the scope of coverage offered by patient medical and pharmaceutical insurance and to identify other financial assistance resources for payment of patient treatment; insurance consultation services, namely, assisting patients and their caregivers to obtain authorization and payment for medical and pharmaceutical costsACTIVEFeb 24, 2023
041Education and training services, namely, seminars, providing non-downloadable webinars, and workshops for healthcare professionals, caregivers, patients, and providers in the field of rare diseases and disorders; online journals, namely, blogs featuring information on rare diseases and disordersACTIVEJan 1, 2021
042Pharmaceutical, scientific, and medical research and development in the field of gene therapy manufacturing technology; biomedical and scientific research in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic diseases, gene therapy, and cell therapy; biomedical research in the field of gene therapy design and delivery; gene therapy design and delivery development of biochemical assays; product development in the fields of genetic therapies and effectors to regulate, modulate, and characterize disease states; pharmaceutical research and development in the field of gene therapy; scientific research in the nature of conducting clinical trials for others in the field of gene therapy design and delivery; scientific and medical research, namely, compiling and sharing of patient data for research purposes in the field of rare diseases and disorders; medical and scientific research information in the field of rare diseases and disorders; computer services, namely, creating an on-line community for registered users to obtain feedback from their peers, interact with research data, and share data in the field of rare diseases and disorders; pharmaceutical research services, namely, recruitment of rare disease patients for panels such as pharmaceutical research panels; providing medical research and scientific research information in the field of hypophosphatemiaACTIVESep 18, 2021
044Providing medical services, namely, gene therapy design and delivery services being gene therapy medical services in the field of liver, hepatological, cardiovascular, central nervous system, endocrine, inflammatory, metabolic, autoimmune, musculoskeletal, neurological, ophthalmologic, respiratory, and hematologic diseases and disorders; medical consulting services in the field of rare diseases and disorders; healthcare services, namely, providing an online database of medical and healthcare information in the field of rare diseases and disorders, and collecting data and information on rare diseases and disorders for screening, diagnosis and treatment purposes; medical information services in the nature of providing a database in the field of hypophosphatemia information based on collected patient data and information all for treatment and diagnostic purposesACTIVESep 10, 2021

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 15, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Aug 19, 2025NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Aug 19, 2025R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jul 31, 2025SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Jul 31, 2025CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Jul 29, 2025SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Jul 29, 2025DPCCDIVISIONAL PROCESSING COMPLETE—
Jul 29, 2025EX2GSOU EXTENSION 2 GRANTED—
Jul 24, 2025AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Jan 16, 2025IUAFUSE AMENDMENT FILED—
Jan 16, 2025DRRRDIVISIONAL REQUEST RECEIVED—
Jan 16, 2025EXT2SOU EXTENSION 2 FILED—
Jan 16, 2025EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Jan 16, 2025ERTDTEAS REQUEST TO DIVIDE RECEIVED—
Jan 16, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Aug 2, 2024EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
Aug 2, 2024TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Aug 2, 2024ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 2, 2024REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Aug 2, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Aug 2, 2024EX1GSOU EXTENSION 1 GRANTED—
Aug 2, 2024EXT1SOU EXTENSION 1 FILED—
Aug 2, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 6, 2024NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Dec 12, 2023NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 12, 2023PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 22, 2023NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 6, 2023CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 3, 2023TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 3, 2023CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 3, 2023TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 25, 2023GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 25, 2023GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 25, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 21, 2023DOCKASSIGNED TO EXAMINER—
Jan 18, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 24, 2022NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance